Proteases of malaria parasites: New targets for chemotherapy

Emerging Infectious Diseases

Volumn 4, Issue 1, 1998, Pages 49-57

  Rosenthal, Philip J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMISININ; ASPARTIC PROTEINASE INHIBITOR; ATOVAQUONE; CHLOROQUINE; CYSTEINE PROTEINASE INHIBITOR; DOXYCYCLINE; FANSIDAR; HALOFANTRINE; HEMOGLOBIN; MALOPRIM; MEFLOQUINE; PRIMAQUINE; PROGUANIL; PROTEINASE; QUININE; TETRACYCLINE DERIVATIVE;

CHEMOPROPHYLAXIS; CHEMOTHERAPY; DRUG TARGETING; ERADICATION THERAPY; ERYTHROCYTE; HUMAN; MALARIA; NEUROTOXICITY; PARASITE DEVELOPMENT; PLASMODIUM; REVIEW; SKIN TOXICITY; TROPHOZOITE;

EID: 0031852685     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0401.980107     Document Type: Review

References (78)

1. Walsh JA. Disease problems in the Third World. Ann N Y Acad Sci 1989;569:1-16.
2. Oaks SC, Mitchell VS, Pearson GW, Carpenter CCJ, editors. Malaria: obstacles and opportunities. Washington: National Academy Press; 1991.
3. Olliaro P, Cattani J, Wirth D. Malaria, the submerged disease. JAMA 1996;275:230-3.
4. Hoffman SL, Miller LH. Perspectives on malaria vaccine development. In: Hoffman SL, editor. Malaria vaccine development. Washington: ASM Press; 1996. p. 1-13.
5. Alonso PL, Lindsay SW, Armstrong JRM, Conteh M, Hill AG, David PH, et al. The effect of insecticide-treated bed nets on mortality of Gambian children. Lancet 1991;337:1499-502.
6. Collins FH, Besansky NJ. Vector biology and the control of malaria in Africa. Science 1994;264:1874-5.
7. Centers for Disease Control. Recommendations for the prevention of malaria among travelers. JAMA 1990;263:2729-40.
8. Murphy GS, Basri H, Purnomo, Andersen EM, Bangs MJ, Mount DL, et al. Vivax malaria resistant to treatment and prophylaxis with chloroquine. Lancet 1993;341:96-100.
9. Panisko DM, Keystone JS. Treatment of malaria -1990. Drugs 1990;39:160-89.
10. Keystone JS. Prevention of malaria. Drugs 1990;39:337-54.
11. Wyler DJ. Malaria chemoprophylaxis for the traveler. N Engl J Med 1993;329:31-7.
12. White JJ. The treatment of malaria. N Engl J Med 1996;335:800-6.
13. Olliaro P, Nevill C, LeBras J, Ringwald P, Mussano P, Garner P, et al. Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet 1996;348:1196-201.
14. Palmer KJ, Holliday SM, Brogden RN. Mefloquine: a review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1993;45:430-75.
15. Luzzi GA, Peto TEA. Adverse effects of antimalarials: an update. Drug Saf 1993;8:295-311.
16. Hellgren U, Kihamia CM, Bergqvist Y, Lebbad M, Premji Z, Rombo L. Standard and reduced doses of sulfadoxine-pyrimethamine for treatment of Plasmodium falciparum in Tanzania, with determination of drug concentrations and susceptibility in vitro. Trans R Soc Trop Med Hyg 1990;84:469-73.
17. Bradley DJ, Warhurst DC. Malaria prophylaxis: guidelines for travellers from Britain. BMJ 1995;310:709-14.
18. Bryson HM, Goa KL. Halofantrine: a review of its antimalarial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992;43:236-58.
19. Meshnick SR, Taylor TE, Kamchonwongpaisan S. Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol Rev 1996;60:301-15.
20. de Vries PJ, Dien TK. Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. Drugs 1996;52:818-36.
21. Haue LG, Flaherty JF. Atovaquone: a review. Ann Pharmacother 1993;27:1488-94.
22. RadloffPD, Philipps J, Nkeyi M, Hutchinson D, Kremsner PG. Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet 1996;347:1511-4.
23. Ringwald P, Bickii J, Basco L. Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa. Lancet 1996;347:24-8.
24. Gordeuk VR, Thuma PE, Brittenham GM, Biemba G, Zulu S, Simwanza G, et al. Iron chelation as a chemotherapeutic strategy for falciparum malaria. Am J Trop Med Hyg 1993;48:193-7.
25. Gordeuk V, Thuma P, Brittenham G, McLaren C, Parry D, Backenstose A, et al. Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. N Engl J Med 1992;327:1473-7.
26. Anderson SL, Berman J, Kuschner R, Wesche D, Magill A, Wellde B, et al. Prophylaxis of Plasmodium falciparum malaria with azithromycin administered to volunteers. Ann Intern Med 1995;123:771-3.
27. McKerrow JH, Sun E, Rosenthal PJ, Bouvier J. The proteases and pathogenicity of parasitic protozoa. Annu Rev Microbiol 1993;47:821-53.
28. 33 as a noncovalently associated complex with other fragments of the MSP1. Mol Biochem Parasitol 1992;50:307-16.
29. Perkins ME. Erythrocyte invasion by the malarial merozoite: recent advances. Exp Parasitol 1989;69:94-9.
30. Bernard F, Schrevel J. Purification of a Plasmodium berghei neutral endopeptidase and its localization in merozoite. Mol Biochem Parasitol 1987;26:167-74.
31. Rosenthal PJ, Kim K, McKerrow JH, Leech JH. Identification of three stage-specific proteinases of Plasmodium falciparum. J Exp Med 1987;166:816-21.
32. Braun-Breton C, Rosenberry TL, Pereira da Silva L. Induction of the proteolytic activity of a membrane protein in Plasmodium falciparum by phosphatidyl inositol-specific phospholipase C. Nature 1988;332:457-9.
33. Roggwiller E, Bétoulle MEM, Blisnick T, Braun Breton C. A role for erythrocyte band 3 degradation by the parasite gp76 serine protease in the formation of the parasitophorous vacuole during invasion of erythrocytes by Plasmodium falciparum. Mol Biochem Parasitol 1996;82:13-24.
34. Deguercy A, Hommel M, Schrevel J. Purification and characterization of 37-kilodalton proteases from Plasmodium falciparum and Plasmodium berghei which cleave erythrocyte cytoskeletal components. Mol Biochem Parasitol 1990;38:233-44.
35. Knapp B, Hundt E, Nau U, Küpper HA. Molecular cloning, genomic structure and localization in a blood stage antigen of Plasmodium falciparum characterized by a serine stretch. Mol Biochem Parasitol 1989;32:73-84.
36. Li W-B, Bzik DJ, Horii T, Inselburg J. Structure and expression of the Plasmodium falciparum SERA gene. Mol Biochem Parasitol 1989;33:13-26.
37. Knapp B, Nau U, Hundt E, Küpper HA. A new blood stage antigen of Plasmodium falciparum highly homologous to the serine-stretch protein SERP. Mol Biochem Parasitol 1991;44:1-14.
38. Roggwiller E, Fricaud A-C, Blisnick T, Braun-Breton C. Host urokinase-type plasminogen activator participates in the release of malaria merozoites from infected erythrocytes. Mol Biochem Parasitol 1997;86:49-59.
39. Schrevel J, Grellier P, Mayer R, Monsigny M. Neutral proteases involved in the reinvasion of erythrocytes by Plasmodium merozoites. Biol Cell 1988;64:233-44.
40. Mayer R, Picard I, Lawton P, Grellier P, Barrault C, Monsigny M, et al. Peptide derivatives specific for a Plasmodium falciparum proteinase inhibit the human erythrocyte invasion by merozoites. J Med Chem 1991;34:3029-35.
41. Francis SE, Gluzman IY, Oksman A, Knickerbocker A, Mueller R, Bryant ML, et al. Molecular characterization and inhibition of a Plasmodium falciparum aspartic hemoglobinase. EMBO J 1994;13:306-17.
42. Moon RP, Tyas L, Certa U, Rupp K, Bur D, Jacquet C, et al. Expression and characterisation of plasmepsin I from Plasmodium falciparum. Eur J Biochem 1997;244:552-60.
43. Silva AM, Lee AY, Gulnik SV, Majer P, Collins J, Bhat TN, et al. Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum. Proc Natl Acad Sci U S A 1996;93:10034-9.
44. Rosenthal PJ, Wollish WS, Palmer JT, Rasnick D. Antimalarial effects of peptide inhibitors of a Plasmodium falciparum cysteine proteinase. J Clin Invest 1991;88:1467-72.
45. Rosenthal PJ, Lee GK, Smith RE. Inhibition of a Plasmodium vinckei cysteine proteinase cures murine malaria. J Clin Invest 1993;91:1052-6.
46. Rosenthal PJ, Olson JE, Lee GK, Palmer JT, Klaus JL, Rasnick D. Antimalarial effects of vinyl sulfone cysteine proteinase inhibitors. Antimicrob Agents Chemother 1996;40:1600-3.
47. Ring CS, Sun E, McKerrow JH, Lee GK, Rosenthal PJ, Kuntz ID, et al. Structure-based inhibitor design by using protein models for the development of antiparasitic agents. Proc Natl Acad Sci USA 1993;90:3583-7.
48. Li R, Kenyon GL, Cohen FE, Chen X, Gong B, Dominguez JN, et al. In vitro antimalarial activity of chalcones and their derivatives. J Med Chem 1995;38:5031-7.
49. Domínguez JN, López S, Charris J, Iarruso L, Lobo G, Semenov A, et al. Synthesis and antimalarial effects of phenothiazine inhibitors of a Plasmodium falciparum cysteine protease. J Med Chem 1997;40:2726-32.
50. Rosenthal PJ, Meshnick SR. Hemoglobin catabolism and iron utilization by malaria parasites. Mol Biochem Parasitol 1996;83:131-9.
51. Slater AFG. Malaria pigment. Exp Parasitol 1992;74:362-5.
52. Bond JS, Butler PE. Intracellular proteases. Annu Rev Biochem 1987;56:333-64.
53. Gluzman IY, Francis SE, Oksman A, Smith CE, Duffin KL, Goldberg DE. Order and specificity of the Plasmodium falciparum hemoglobin degradation pathway. J Clin Invest 1994;93:1602-8.
54. Gyang FN, Poole B, Trager W. Peptidases from Plasmodium falciparum cultured in vitro. Mol Biochem Parasitol 1982;5:263-73.
55. Aissi E, Charet P, Bouquelet S, Biguet J. Endoprotease in Plasmodium yoelii nigeriensis. Comp Biochem Physiol 1983;74B:559-66.
56. Sherman IW, Tanigoshi L. Purification of Plasmodium lophurae cathepsin D and its effects on erythrocyte membrane proteins. Mol Biochem Parasitol 1983;8:207-26.
57. Sato K, Fukabori Y, Suzuki M. Plasmodium berghei: a study of globinolytic enzyme in erythrocytic parasite. Zbl Bakt Hyg A 1987;264:487-95.
58. Bailly E, Savel J, Mahouy G, Jaureguiberry G. Plasmodium falciparum: isolation and characterization of a 55-kDa protease with a cathepsin D-like activity from P. falciparum. Exp Parasitol 1991;72:278-84.
59. Goldberg DE, Slater AFG, Beavis R, Chait B, Cerami A, Henderson GB. Hemoglobin degradation in the human malaria pathogen Plasmodium falciparum: a catabolic pathway initiated by a specific aspartic protease. J Exp Med 1991;173:961-9.
60. Vander Jagt DL, Hunsaker LA, Campos NM, Scaletti JV. Localization and characterization of hemoglobin-degrading aspartic proteinases from the malarial parasite Plasmodium falciparum. Biochim Biophys Acta 1992;1122:256-64.
61. Dame JB, Reddy GR, Yowell CA, Dunn BM, Kay J, Berry C. Sequence, expression and modeled structure of an aspartic proteinase from the human malaria parasite Plasmodium falciparum. Mol Biochem Parasitol 1994;64:177-90.
62. Hill J, Tyas L, Phylip LH, Kay J, Dunn BM, Berry C. High level expression and characterisation of plasmepsin II, an aspartic proteinase from Plasmodium falciparum. FEBS Lett 1994;352:155-8.
63. Dluzewski AR, Rangachari K, Wilson RJM, Gratzer WB. Plasmodium falciparum: protease inhibitors and inhibition of erythrocyte invasion. Exp Parasitol 1986;62:416-22.
64. Rosenthal PJ, McKerrow JH, Aikawa M, Nagasawa H, Leech JH. A malarial cysteine proteinase is necessary for hemoglobin degradation by Plasmodium falciparum. J Clin Invest 1988;82:1560-6.
65. Vander Jagt DL, Caughey WS, Campos NM, Hunsaker LA, Zanner MA. Parasite proteases and antimalarial activities of protease inhibitors. Prog Clin Biol Res 1989;313:105-18.
66. Rosenthal PJ. Plasmodium falciparum: effects of proteinase inhibitors on globin hydrolysis by cultured malaria parasites. Exp Parasitol 1995;80:272-81.
67. Bailly E, Jambou R, Savel J, Jaureguiberry G. Plasmodium falciparum: differential sensitivity in vitro to E-64 (cysteine protease inhibitor) and pepstatin A (aspartyl protease inhibitor). Journal of Protozoology 1992;39:593-9.
68. Gamboa de Domínguez ND, Rosenthal PJ. Cysteine proteinase inhibitors block early steps in hemoglobin degradation by cultured malaria parasites. Blood 1996;87:4448-54.
69. Asawamahasakda W, Ittarat I, Chang C-C, McElroy P, Meshnick SR. Effects of antimalarials and protease inhibitors on plasmodial hemozoin production. Mol Biochem Parasitol 1994;67:183-91.
70. Rosenthal PJ, McKerrow JH, Rasnick D, Leech JH. Plasmodium falciparum: inhibitors of lysosomal cysteine proteinases inhibit a trophozoite proteinase and block parasite development. Mol Biochem Parasitol 1989;35:177-84.
71. Salas F, Fichmann J, Lee GK, Scott MD, Rosenthal PJ. Functional expression of falcipain, a Plasmodium falciparum cysteine proteinase, supports its role as a malarial hemoglobinase. Infect Immun 1995;63:2120-5.
72. Francis SE, Gluzman IY, Oksman A, Banerjee D, Goldberg DE. Characterization of native falcipain, an enzyme involved in Plasmodium falciparum hemoglobin degradation. Mol Biochem Parasitol 1996;83:189-200.
73. Rosenthal PJ, Nelson RG. Isolation and characterization of a cysteine proteinase gene of Plasmodium falciparum. Mol Biochem Parasitol 1992;51:143-52.
74. Kamchonwongpaisan S, Samoff E, Meshnick SR. Identification of hemoglobin degradation products in Plasmodium falciparum. Mol Biochem Parasitol 1997;86:179-86.
75. Vander Jagt DL, Baack BR, Hunsaker LA. Purification and characterization of an aminopeptidase from Plasmodium falciparum. Mol Biochem Parasitol 1984;10:45-54.
76. Curley GP, O'Donovan SM, McNally J, Mullally M, O'Hara H, Troy A, et al. Aminopeptidases from Plasmodium, falciparum, Plasmodium, chabaudi, and Plasmodium berghei. J Eukaryot Microbiol 1994;41:119-23.
77. Kolakovich KA, Gluzman IY, Duffin KL, Goldberg DE. Generation of hemoglobin peptides in the acidic digestive vacuole of Plasmodium falciparum implicates peptide transport in amino acid production. Mol Biochem Parasitol 1997;87:123-35.
78. Rockett KA, Playfair JHL, Ashall F, Targett GAT, Angliker H, Shaw E. Inhibition of intraerythrocytic development of Plasmodium falciparum by proteinase inhibitors. FEBS Lett 1990;259:257-9.